Review article: Gastroenterology and the pharmaceutical industry

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 11, 2002, Pages 1859-1866

  Rakatansky, H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; ROFECOXIB;

CLINICAL RESEARCH; CONSUMER; DRUG INDUSTRY; DRUG MARKETING; ETHICS; FINANCIAL MANAGEMENT; GASTROENTEROLOGY; HEALTH CARE ORGANIZATION; MEDICAL EDUCATION; PATIENT CARE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STANDARD;

CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, MEDICAL; ETHICS, RESEARCH; GASTROENTEROLOGY; HUMANS; MARKETING; PERIODICALS; RESEARCH SUPPORT;

EID: 0036829714     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01362.x     Document Type: Review

References (52)

1. Opinion 10.015. AMA Code of Medical Ethics. Chicago, IL: American Medical Association.
2. Prescription Drugs and Mass Media Advertising. 2000. Washington DC: National Institute for Health Care Management. 2000.
3. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Washington DC: National Institute for Health Care Management. 2001.
4. Schmidt CW. Have I got a drug for you. Modern Drug Discovery 2001; 4(12): 41-2.
5. Memoirs of Methods Used to Sell Drugs. Medical Lobby for Appropriate Marketing 17 no. 3/4, 1999, accessed at http://www.camtgch.net/malam/in9903.htm.
6. Marketing Plans for Medicinal Products Available on Prescription Only: The Current Situation. 2nd edn. The Hague: Health Care Inspectorate. 2001.
7. Gammage J, Stark K. Under the influence. Philadelphia Inquirer (Magazine Section) 2002; March 15.
8. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? J Am Med Assoc 2000; 283: 373-80.
9. De Laat E, Windmeijer F, Douven R. How Does Pharmaceutical Marketing Influence Doctors' Behavior? The Hague: CPB-Netherlands Bureau for Economic Policy Analysis, 2002.
10. Quoted in Haak H. Pharmaceutical marketing and prescribing behavior. E-Drug-Digest 2002; 1(649).
11. Banks JW, Mainous AG 3rd. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Acad Med 1992; 67(9): 610-2.
12. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Int Med 1998; 3: 213-5.
13. Coyle SL. Physician-industry relations. Part 1: individual physicians. Ann Intern Med 2002; 136: 396-402.
14. The Council on Ethical and Judicial Affairs of the American Medical Association. Guidelines on gifts to physicians from industry: an update. Food Drug Law J 2001; 56(1): 27-40.
15. Sheldon T. Drug company fined for excessive hospitality. Br Med J 2001; 322: 382.
16. Dinsdale P. Pfizer gets a public dressing down over promoting unlicensed drugs. Br Med J 2002; 324: 753.
17. PhRMA Code on Interactions with Healthcare Professionals. Washington DC: Pharmaceutical Research and Manufacturers of America. 2002.
18. Martin JB, Kasper DL. In whose best interest? Breaching the academic-industrial wall. N Engl J Med 2000; 343: 1646-9.
19. Morin K, Rakatansky H, Riddick FA, et al. Managing conflicts of interest in the conduct of clinical trials. J Am Med Assoc 2002; 287(1): 78-84.
20. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. J Am Med Assoc 2001; 286(1): 89-91.
21. Biomedical Research HHS. Direction Needed to Address Financial Conflicts of Interest. Report to the Ranking Minority Member. Washington DC: Subcommittee on Public Health. Education, Labor. and Pensions, US Senate. United States General Accounting Office. Report no. 02-89. November 2001.
22. Task Force on Financial Conflicts of Interest in Clinical Research Protecting Subjects, Preserving Trust, Promoting Progress. Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research. Washington DC: Association of American Medical Colleges. 2001.
23. Kelch RP. Maintaining the public trust in clinical research. N Engl J Med 2002; 346(4): 285-7.
24. Bodenheimer T. Uneasy alliance: Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342(20): 1539-44.
25. Lo B, Wolf LE, Berkeley A. Conflict of interest policies for investigators in clinical trials. N Engl J Med Year?; 343(22): 1616-20.
26. Boyd EA, Bero LA. Assessing faculty financial interests with industry. J Am Med Assoc 2000; 284(17): 2209-14.
27. Campbell EG, Louis KS. Blumenthal D. Looking a gift horse in the mouth. Corporate gifts supporting life science research. J Am Med Assoc 1998; 279(13): 995.
28. Blumenthal D, Campbell EG, Anderson MS. et al. Withholding research results in academic life science. Evidence from a national survey of faculty. J Am Med Assoc 1997; 285(17): 2192-3.
29. Mcrary S Van, Anderson CB. Jakovljevic, J. et al. A national survey of policies on disclosure of conflicts of interest in biomedical research. N Engl J Med 2000; 343(22): 1621-6.
30. Bero LA. Disclosure policies for gifts from industry to academic faculty. J Am Med Assoc 1998; 279(13): 1031-2.
31. International Committee of Medical Journal Editors. Sponsorship, Authorship, and Accountability. 2000. accessed at http://www.icmje.org/sponsor.
32. Opinion 6.03. AMA Code of Medical Ethics. Chicago, IL: American Medical Association.
33. Council on Governmental Relations. The Bay-Dole Act: A Guide to the Law and Implementing Regulations. Washington, DC: Council on Governmental Relations. 1999. accessed at http://cogr.edu/bayh-dole.htm.
34. Association of University Technology Managers. AUTM Licensing Survey: FY 2000, Northbrook, IL: Association of University Technology Managers, 2000.
35. Blunenstyk G. Turning patent royalties into a sure thing. Chronicle of Higher Education 2001; 48, accessed at http://chronicle.com/weekly/v48/1O6/O6aO2601.htm.
36. Cho MK, Shohara R, Schissell A. et al. Policies on faculty conflicts of interest at US universities. J Am Med Assoc 2000; 284(17): 2203-8.
37. Davidoff F, DeAngelis CD, Drazen JM. et al. Sponsorship, authorship, and accountability. J Am Med Assoc 2001; 286(10): 1232-4.
38. Statement on Corporate Funding of Academic Research. Washington, DC: American Association of University Professors.
39. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. J Am Med Assoc 2002; 287(5): 612-7.
40. Gastroenterology: Copyright Assignment, Authorship Responsibility, Financial Disclosure, and Institutional Review Board/Animal Care Committee Approval. 2002. accessed at http://www.harcourthealth.com/periodicals/pubs/0016-5085/pdfs/copyright.html.
41. Instructions to authors. Gastrointest Endosc 2002; 56(3): 35A-9A.
42. Instructions for authors. Aliment Pharmacol Ther 2002. accessed at http://www.medirect.com/∼cgilib/journal.asp?subj=gast&; journal=apt&page=authors.
43. Instructions to authors. Hepatology 2002; 35(5).
44. Conflicts of Interest and the Peer Review Process. Reston, VA: Council of Scientific Editors. 2000.
45. Just how tainted has medicine become? Lancet 2002; 359(9313): 1167.
46. Godlee F. Making reviewers visible. J Am Med Assoc 2002; 287(21): 2762-5.
47. The Committee on Publication Ethics. Guidelines on Good Publication Practice, 2001, accessed at http://www.publicationethics.org.uk/cope2001/pdf2001/page54.pdf.
48. National Working Group. AMA Institute for Ethics. Organizational Ethics in Healthcare, 2002, accessed at http://www.ama-assn.org/ama/pub/category/2735.html.
49. Pellegrino ED, Relman AS. Professional medical associations ethical and practical guidelines. J Am Med Assoc 1999; 282(10): 984-6.
50. Guidelines on Relationships with the Pharmaceutical and Medical Device Industries (Approved by AGA Foundation Board of Directors). Bethesda, MD: AGA, November 1993.
51. Standards for Commercial Support of Continuing Medical Education, Chicago, IL: Accreditation Council for Continuing Medical Education, August 1999.
52. Relman AS. Separating continuing medical education from pharmaceutical marketing. J Am Med Assoc 2002; 285(15): 2009-12.